Oncology Based Preclinical Cro Market Size Projected to Reach $1716.36 million by 2034 | 13.67%

According to Straits Research, the global oncology based preclinical CRO market size was valued at $543.55 million in 2025 and is projected to grow from $615.89 million in 2026 to $1,716.36 million by 2034, registering a CAGR of 13.67% during the forecast period 2026–2034.

Market Dynamics

The global oncology-based preclinical CRO market is driven by the increasing prevalence of cancer worldwide, rising demand for targeted therapies and immuno-oncology drugs, and growing outsourcing of preclinical studies to contract research organizations offering specialized in vitro and in vivo oncology models. Additionally, advancements in biomarker analysis, translational research, and the integration of AI and 3D organoid models are further accelerating market growth. However, the market faces restraints such as the high cost of complex preclinical studies, stringent regulatory and ethical guidelines for animal testing, and challenges in translating preclinical results to clinical success. Nevertheless, expanding R&D investments, increasing collaborations between pharma companies and CROs, and the emergence of cost-effective outsourcing destinations in the Asia-Pacific present significant opportunities for market expansion and innovation.

Market Segments

1. By Type (2026-2034)
   1. Blood Cancer
   2. Solid Tumors
   3. Others
2. By Application (2026-2034)
   1. In Vitro
   2. In Vivo